{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:35:41Z","timestamp":1785800141368,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T00:00:00Z","timestamp":1518220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00228-018-2429-1","type":"journal-article","created":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T01:51:36Z","timestamp":1518227496000},"page":"663-670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3760-6423","authenticated-orcid":false,"given":"Irene","family":"Eriksson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Komen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Piehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rickard E.","family":"Malmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Wettermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"von Euler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,10]]},"reference":[{"issue":"1","key":"2429_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s13311-012-0163-4","volume":"10","author":"CA McGraw","year":"2013","unstructured":"McGraw CA, Lublin FD (2013) Interferon beta and glatiramer acetate therapy. Neurotherapeutics 10(1):2\u201318. \n                    https:\/\/doi.org\/10.1007\/s13311-012-0163-4","journal-title":"Neurotherapeutics"},{"issue":"5","key":"2429_CR2","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/jim-2016-000339","volume":"65","author":"DL Vargas","year":"2017","unstructured":"Vargas DL, Tyor WR (2017) Update on disease-modifying therapies for multiple sclerosis. J Investig Med 65(5):883\u2013891. \n                    https:\/\/doi.org\/10.1136\/jim-2016-000339","journal-title":"J Investig Med"},{"issue":"20","key":"2429_CR3","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1212\/WNL.0000000000003345","volume":"87","author":"D Bourdette","year":"2016","unstructured":"Bourdette D (2016) Rituximab for treating multiple sclerosis: off-label but on target. Neurology 87(20):2070\u20132071. \n                    https:\/\/doi.org\/10.1212\/wnl.0000000000003345","journal-title":"Neurology"},{"key":"2429_CR4","unstructured":"Stockholm County Drug and Therapetics Committee (2015) Dimetylfumarat (Tecfidera) som sjukdomsmodulerande behandling vid MS b\u00f6r fr\u00e4mst anv\u00e4ndas till patienter under 40 \u00e5r med aktiv skovvis f\u00f6rl\u00f6pande sjukdom utan h\u00f6ginflammatorisk aktivitet. \n                    http:\/\/www.janusinfo.se\/Behandling\/Expertradsutlatanden\/Neurologiska-sjukdomar\/Dimetylfumarat-Tecfidera-som-sjukdomsmodulerande-behandling-vid-MS-bor-framst-anvandas-till-patienter-under-40-ar-med-aktiv-skovvis-forlopande-sjukdom-utan-hoginflammatorisk-aktivitet\/"},{"issue":"4","key":"2429_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/j.1365-2710.2008.00925.x","volume":"33","author":"D Chauhan","year":"2008","unstructured":"Chauhan D, Mason A (2008) Factors affecting the uptake of new medicines in secondary care\u2014a literature review. J Clin Pharm Ther 33(4):339\u2013348. \n                    https:\/\/doi.org\/10.1111\/j.1365-2710.2008.00925.x","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"2429_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-14-469","volume":"14","author":"A Lubloy","year":"2014","unstructured":"Lubloy A (2014) Factors affecting the uptake of new medicines: a systematic literature review. BMC Health Serv Res 14(1):469. \n                    https:\/\/doi.org\/10.1186\/1472-6963-14-469","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"2429_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00228-017-2366-4","volume":"74","author":"I Eriksson","year":"2018","unstructured":"Eriksson I, Cars T, Piehl F, Malmstrom RE, Wettermark B, von Euler M (2018) Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study. Eur J Clin Pharmacol 74(2):219\u2013226. \n                    https:\/\/doi.org\/10.1007\/s00228-017-2366-4","journal-title":"Eur J Clin Pharmacol"},{"key":"2429_CR8","unstructured":"Swedish Association of Local Authorities and Regions (2015) Individdata om rekvisitionsl\u00e4kemedel: uppf\u00f6ljning, dokumentation och informatik. \n                    https:\/\/skl.se\/halsasjukvard\/lakemedel\/nyhetsarkivlakemedel\/arkivlakemedel\/uppfoljningenavlakemedelsanvandningkanforbattras.5123.html"},{"issue":"4","key":"2429_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","volume":"27","author":"AK Wagner","year":"2002","unstructured":"Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D (2002) Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 27(4):299\u2013309. \n                    https:\/\/doi.org\/10.1046\/j.1365-2710.2002.00430.x","journal-title":"J Clin Pharm Ther"},{"key":"2429_CR10","unstructured":"Box GE, Jenkins GM (1976) Time series analysis: forecasting and control, revised ed. Holden-Day series in time series analysis and digital signal processing. Holden-Day, San Francisco"},{"issue":"1\/2","key":"2429_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2332325","volume":"38","author":"J Durbin","year":"1951","unstructured":"Durbin J, Watson GS (1951) Testing for serial correlation in least squares regression. II. Biometrika 38(1\/2):159\u2013177. \n                    https:\/\/doi.org\/10.2307\/2332325","journal-title":"Biometrika"},{"key":"2429_CR12","doi-asserted-by":"publisher","DOI":"10.4135\/9781412984607","volume-title":"Interrupted time series analysis, vol 21. Quantitative Applications in the Social Sciences","author":"D McDowall","year":"1980","unstructured":"McDowall D, McCleary R, Meidinger E, Hay RA (1980) Interrupted time series analysis, vol 21. Quantitative Applications in the Social Sciences. Sage Publications, Beverly Hills and London. \n                    https:\/\/doi.org\/10.4135\/9781412984607"},{"issue":"1","key":"2429_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/1352458512469700","volume":"19","author":"RJ Fox","year":"2013","unstructured":"Fox RJ (2013) In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yes. Mult Scler J 19(1):24\u201325. \n                    https:\/\/doi.org\/10.1177\/1352458512469700","journal-title":"Mult Scler J"},{"key":"2429_CR14","unstructured":"Dental and Pharmaceutical Benefits Agency (2017) Pricing and reimbursement decisions. \n                    www.tlv.se\/beslut\/"},{"key":"2429_CR15","unstructured":"Stockholm County Drug and Therapetics Committee (2017) The Wise List. \n                    http:\/\/klokalistan.janusinfo.se\/2017\/"},{"key":"2429_CR16","doi-asserted-by":"publisher","unstructured":"Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, Piehl F (2018) Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. \n                    https:\/\/doi.org\/10.1001\/jamaneurol.2017.4011","DOI":"10.1001\/jamaneurol.2017.4011"},{"issue":"6","key":"2429_CR17","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/ana.24651","volume":"79","author":"P Alping","year":"2016","unstructured":"Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Bjorck A, Axelsson M, Malmestrom C, Fink K, Lycke J, Svenningsson A, Piehl F (2016) Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 79(6):950\u2013958. \n                    https:\/\/doi.org\/10.1002\/ana.24651","journal-title":"Ann Neurol"},{"issue":"3","key":"2429_CR18","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bcp.13150","volume":"83","author":"J Komen","year":"2017","unstructured":"Komen J, Forslund T, Hjemdahl P, Andersen M, Wettermark B (2017) Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. Br J Clin Pharmacol 83(3):642\u2013652. \n                    https:\/\/doi.org\/10.1111\/bcp.13150","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2429_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2710.2008.00875.x","volume":"33","author":"A Mason","year":"2008","unstructured":"Mason A (2008) New medicines in primary care: a review of influences on general practitioner prescribing. J Clin Pharm Ther 33(1):1\u201310. \n                    https:\/\/doi.org\/10.1111\/j.1365-2710.2008.00875.x","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"2429_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-014-0199-0","volume":"15","author":"V Milos","year":"2014","unstructured":"Milos V, Westerlund T, Midlov P, Strandberg EL (2014) Swedish general practitioners\u2019 attitudes towards treatment guidelines\u2014a qualitative study. BMC Fam Pract 15(1):199. \n                    https:\/\/doi.org\/10.1186\/s12875-014-0199-0","journal-title":"BMC Fam Pract"},{"issue":"1","key":"2429_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00228-017-2354-8","volume":"74","author":"J Eriksen","year":"2018","unstructured":"Eriksen J, Ovesjo ML, Vallin M, Juhasz-Haverinen M, Andersen-Karlsson E, Ateva K, Gustafsson LL, Jirlow M, Bastholm-Rahmner P (2018) Primary care physicians report high trust in and usefulness of the Stockholm drug and therapeutic committee\u2019s list of recommended essential medicines (the \u2018Wise List\u2019). Eur J Clin Pharmacol 74(1):131\u2013138. \n                    https:\/\/doi.org\/10.1007\/s00228-017-2354-8","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"2429_CR22","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.jclinepi.2014.12.018","volume":"68","author":"R Jandoc","year":"2015","unstructured":"Jandoc R, Burden AM, Mamdani M, Levesque LE, Cadarette SM (2015) Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations. J Clin Epidemiol 68(8):950\u2013956. \n                    https:\/\/doi.org\/10.1016\/j.jclinepi.2014.12.018","journal-title":"J Clin Epidemiol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2429-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2429-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2429-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T20:10:57Z","timestamp":1549743057000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2429-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,10]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["2429"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2429-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,10]]},"assertion":[{"value":"15 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the regional ethics board in Stockholm, Sweden (ref. no. 2015-2329-31-4).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MvE and FP wrote the DTC recommendation on dimethyl fumarate and are members of the regional DTC neurological diseases committee. FP is also a member of the Swedish MS Association and contributed to writing the national recommendations issued by the Swedish MS Association. FP has received unrestricted academic research grants from Biogen, Genzyme, and Novartis, and on behalf of FP, his department has received travel support and\/or compensation for lectures from Biogen, Genzyme, Merck Serono, Novartis, Roche, and Teva, which have been exclusively used for the support of research activities. IE, JK, BW, and RM declare no COI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}